DNA testing in general. H.R. 988/S. 517, Katie Sepich Enhanced DNA Collection Act of 2011.
Laboratory testing in general. FDA regulations in general.
NIH funding in general and effect of sequestration.
H.R. 6014/ S. 250, Katie Sepich Enhanced DNA Collection Act of 2012, Title II.
DNA testing in general. H.R. 988/S. 517, the Katie Sepich Enhanced DNA Collection Act of 2011.
H.R. 6014/ S. 250, Katie Sepich Enhanced DNA Collection Act of 2012, Title II.
Changes to tax code affecting corporate tax structure and international deferral.
Laboratory testing in general. FDA regulations in general. NIH funding in general and effect of sequestration.
FY13 Labor HHS appropriations, NIH funding. NIH funding in general and effect of sequestration.
Duration: November 1, 2007
to
December 31, 2012
General Issues: Science/Technology , Law Enforcement/Crime/Criminal Justice , Taxation/Internal Revenue Code , Health Issues , Budget/Appropriations , Copyright/Patent/Trademark , Financial Institutions/Investments/Securities , Agriculture , Food Industry (Safety, Labeling, etc.)
Spending: about $595,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2007: House of Representatives, U.S. Senate, Y
Y
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Cristina Krasow
Senior Assist., Sen. Democratic Cloakroom
Executive Office, Senate Sergeant at Arms
Jeff Peck
Staff Director, Senate Judiciary Committee
Andrew McKechnie
Health Policy Advisor, Sen. Finance Committee
Legislative Assistant, Senator Norm Coleman
Legislative Assistant, Rep. Jim Ramstad
Bipartisan Medical Technology Caucus
Drew Cantor
Press Secretary, Rep. Sue Kelly
Sr. Comms. Advisor, Sen. Republican Conference
Justin McCarthy
Legislative Correspondent, Rep. Thomas Ewing
Legislative Assistant, Rep. Thomas Ewing
Assist. USTR, Intergovernmental and Pub. Affairs
Assistant USTR, Congressional Affairs
Special Assistant to the President, Leg. Affairs
Special Assist. to the President, Legis. Affairs
Janet Mullins Grissom
Assist. Sec., Leg. Affairs, State Department
Chief of Staff, Senator Mitch McConnell
Chief of Staff, Senator Bob Packwood
Assist. to the President, Political Affairs
JOHN LAMPMANN
n/a
Jeffrey Peck
n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2012
Peck Madigan Jones terminated an engagement in which they represented LIFE TECHNOLOGIES CORPORATION on Jan. 22, 2013.
Original Filing: 300539207.xml
Lobbying Issues
DNA testing in general. H.R. 988/S. 517, Katie Sepich Enhanced DNA Collection Act of 2011.
Laboratory testing in general. FDA regulations in general.
NIH funding in general and effect of sequestration.
H.R. 6014/ S. 250, Katie Sepich Enhanced DNA Collection Act of 2012, Title II.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
DNA testing in general. H.R. 988/S. 517, the Katie Sepich Enhanced DNA Collection Act of 2011.
H.R. 6014/ S. 250, Katie Sepich Enhanced DNA Collection Act of 2012, Title II.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Changes to tax code affecting corporate tax structure and international deferral.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Laboratory testing in general. FDA regulations in general. NIH funding in general and effect of sequestration.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
FY13 Labor HHS appropriations, NIH funding. NIH funding in general and effect of sequestration.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2012
In Q3, Peck Madigan Jones (formerly Peck, Madigan, Jones & Stewart, Inc.) lobbied for LIFE TECHNOLOGIES CORPORATION , earning $20,000. The report was filed on Oct. 22, 2012.
Original Filing: 300520685.xml
Lobbying Issues
DNA testing in general. H.R. 988/S. 517, Katie Sepich Enhanced DNA Collection Act of 2011.
Laboratory testing in general. FDA regulations in general.
NIH funding in general and effect of sequestration.
H.R. 6014/ S. 250, Katie Sepich Enhanced DNA Collection Act of 2012, Title II.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
DNA testing in general. H.R. 988/S. 517, the Katie Sepich Enhanced DNA Collection Act of 2011.
H.R. 6014/ S. 250, Katie Sepich Enhanced DNA Collection Act of 2012, Title II.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Changes to tax code affecting corporate tax structure and international deferral.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Laboratory testing in general. FDA regulations in general. NIH funding in general and effect of sequestration.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
FY13 Labor HHS appropriations, NIH funding. NIH funding in general and effect of sequestration.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2012
In Q2, Peck, Madigan, Jones & Stewart, Inc. lobbied for LIFE TECHNOLOGIES CORPORATION , earning $20,000. The report was filed on July 20, 2012.
Original Filing: 300495716.xml
Lobbying Issues
DNA testing in general. H.R. 988/S. 517, Katie Sepich Enhanced DNA Collection Act of 2011.
Laboratory testing in general. FDA regulations in general.
NIH funding in general and effect of sequestration.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
DNA testing in general. H.R. 988/S. 517, the Katie Sepich Enhanced DNA Collection Act of 2011.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Changes to tax code affecting corporate tax structure and international deferral.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Laboratory testing in general. FDA regulations in general. NIH funding in general and effect of sequestration. S. 3187, Food and Drug Administration Safety and Innovation Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
FY13 Labor HHS appropriations, NIH funding. NIH funding in general and effect of sequestration.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2012
In Q1, Peck, Madigan, Jones & Stewart, Inc. lobbied for LIFE TECHNOLOGIES CORPORATION , earning $30,000. The report was filed on April 20, 2012.
Original Filing: 300474880.xml
Lobbying Issues
DNA testing in general. H.R. 988/S. 517, Katie Sepich Enhanced DNA Collection Act of 2011.
Laboratory testing in general. FDA regulations in general.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
DNA testing in general. H.R. 988/S. 517, the Katie Sepich Enhanced DNA Collection Act of 2011.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Changes to tax code affecting corporate tax structure and international deferral.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Laboratory testing in general. FDA regulations in general.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
FY13 Labor HHS appropriations, NIH funding.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2011
In Q4, Peck, Madigan, Jones & Stewart, Inc. lobbied for LIFE TECHNOLOGIES CORPORATION , earning $50,000. The report was filed on Jan. 20, 2012.
Original Filing: 300450865.xml
Lobbying Issues
DNA testing in general. H.R. 988/S. 517, Katie Sepich Enhanced DNA Collection Act of 2011.
Laboratory testing in general. FDA regulations in general.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
DNA testing in general. H.R. 988/S. 517, the Katie Sepich Enhanced DNA Collection Act of 2011.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Changes to tax code affecting corporate tax structure and international deferral.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Laboratory testing in general. FDA regulations in general.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
FY12 Labor HHS appropriations, NIH funding.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2011
In Q3, Peck, Madigan, Jones & Stewart, Inc. lobbied for LIFE TECHNOLOGIES CORPORATION , earning $50,000. The report was filed on Oct. 20, 2011.
Original Filing: 300425426.xml
Lobbying Issues
S. 23, America Invents Act; false markings provision. H.R. 1249, Leahy-Smith America Invents Act; false markings provision. H.R. 1056, Patent Continuing Disclosure Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
S. 23, America Invents Act; false markings provision. H.R. 1249, To amend title 35, United States Code, to provide for patent reform; false markings provision. H.R. 1056, Patent Continuing Disclosure Act.
DNA testing in general. H.R. 988/S. 517, Katie Sepich Enhanced DNA Collection Act of 2011.
Laboratory testing in general. FDA regulations in general.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
DNA testing in general. H.R. 988/S. 517, the Katie Sepich Enhanced DNA Collection Act of 2011.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Changes to tax code affecting corporate tax structure and international deferral.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Laboratory testing in general. FDA regulations in general.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
FY12 Labor HHS appropriations, NIH funding.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2011
In Q2, Peck, Madigan, Jones & Stewart, Inc. lobbied for LIFE TECHNOLOGIES CORPORATION , earning $40,000. The report was filed on July 20, 2011.
Original Filing: 300402718.xml
Lobbying Issues
S. 23, America Invents Act; false markings provision. H.R. 1249, Leahy-Smith America Invents Act; false markings provision. H.R. 1056, Patent Continuing Disclosure Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
S. 23, America Invents Act; false markings provision. H.R. 1249, To amend title 35, United States Code, to provide for patent reform; false markings provision. H.R. 1056, Patent Continuing Disclosure Act.
DNA testing in general. H.R. 988/S. 517, Katie Sepich Enhanced DNA Collection Act of 2011.
Dissemination of Battelle and United for Medical Research reports on economic impact of scientific research.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
DNA testing in general. H.R. 988/S. 517, the Katie Sepich Enhanced DNA Collection Act of 2011.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Changes to tax code affecting corporate tax structure and international deferral.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2011
In Q1, Peck, Madigan, Jones & Stewart, Inc. lobbied for LIFE TECHNOLOGIES CORPORATION , earning $30,000. The report was filed on April 20, 2011.
Original Filing: 300378386.xml
Lobbying Issues
S. 23, America Invents Act; false markings provision. H.R. 1249, To amend title 35, United States Code, to provide for patent reform; false markings provision. H.R. 1056, Patent Continuing Disclosure Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
S. 23, America Invents Act; false markings provision. H.R. 1249, To amend title 35, United States Code, to provide for patent reform; false markings provision. H.R. 1056, Patent Continuing Disclosure Act.
DNA testing in general.
H.R. 988/S. 517, Katie Sepich Enhanced DNA Collection Act of 2011.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
DNA testing in general. H.R. 988/S. 517, the Katie Sepich Enhanced DNA Collection Act of 2011.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Changes to tax code affecting corporate tax structure and international deferral.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Corporate governance provisions in S. 3217, Restoring American Financial Stability Act. Corporate governance provisions in H.R. 4173, Dodd-Frank Wall Street Reform and Consumer Protection Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Financial Institutions/Investments/Securities
4th Quarter, 2010
In Q4, Peck, Madigan, Jones & Stewart, Inc. lobbied for LIFE TECHNOLOGIES CORPORATION , earning $30,000. The report was filed on Jan. 20, 2011.
Original Filing: 300353767.xml
Lobbying Issues
H.R.1260/S.515, Patent Reform Act of 2009; false markings provision. H.R. 4954, To amend title 35, United States Code, to provide recourse under the patent law for persons who suffer competitive injury as a result of false markings.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R.1260/S.515, Patent Reform Act of 2009; false markings provision. H.R. 4954, To amend title 35, United States Code, to provide recourse under the patent law for persons who suffer competitive injury as a result of false markings.
DNA testing in general.
H.R. 4614/S. 3805, Katie Sepich Enhanced DNA Collection Act of 2010.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
DNA testing in general. H.R. 4614/S. 3805, the Katie Sepich Enhanced DNA Collection Act of 2010.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Changes to tax code affecting international deferral.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Corporate governance provisions in S. 3217, Restoring American Financial Stability Act. Corporate governance provisions in H.R. 4173, Dodd-Frank Wall Street Reform and Consumer Protection Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Financial Institutions/Investments/Securities
3rd Quarter, 2010
In Q3, Peck, Madigan, Jones & Stewart, Inc. lobbied for LIFE TECHNOLOGIES CORPORATION , earning $30,000. The report was filed on Oct. 20, 2010.
Original Filing: 300326821.xml
Lobbying Issues
H.R.1260/S.515, Patent Reform Act of 2009; false marketings provision.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R.1260/S.515, Patent Reform Act of 2009; false marketings provision.
DNA testing in general.
H.R. 4614/S. 3805, Katie Sepich Enhanced DNA Collection Act of 2010.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
DNA testing in general. H.R. 4614/S. 3805, the Katie Sepich Enhanced DNA Collection Act of 2010.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Changes to tax code affecting international deferral.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Corporate governance provisions in S. 3217, Restoring American Financial Stability Act. Corporate governance provisions in H.R. 4173, Dodd-Frank Wall Street Reform and Consumer Protection Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Financial Institutions/Investments/Securities
2nd Quarter, 2010
In Q2, Peck, Madigan, Jones & Stewart, Inc. lobbied for LIFE TECHNOLOGIES CORPORATION , earning $30,000. The report was filed on July 20, 2010.
Original Filing: 300299726.xml
Lobbying Issues
H.R.1260/S.515, Patent Reform Act of 2009; and Research Use Exemption.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R.1260/S.515, Patent Reform Act of 2009; and Research Use Exemption.
DNA testing in general.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R.2749, Food Safety Enhancement Act of 2009; and S.510, FDA Food Safety Modernization Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Agriculture Food Industry (Safety, Labeling, etc.)
Lobbying Issues
DNA testing in general. H.R. 4614, the Katie Sepich Enhanced DNA Collection Act of 2010.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Changes to tax code affecting international deferral.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Corporate governance provisions in S. 3217, Restoring American Financial Stability Act. Corporate governance provisions in the Dodd-Frank Wall Street Reform and Consumer Protection Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Financial Institutions/Investments/Securities
1st Quarter, 2010
In Q1, Peck, Madigan, Jones & Stewart, Inc. lobbied for LIFE TECHNOLOGIES CORPORATION , earning $30,000. The report was filed on April 20, 2010.
Original Filing: 300271260.xml
Lobbying Issues
H.R.1260/S.515, Patent Reform Act of 2009; and Research Use Exemption.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R.1260/S.515, Patent Reform Act of 2009; and Research Use Exemption.
DNA testing in general.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R.2749, Food Safety Enhancement Act of 2009; and S.510, FDA Food Safety Modernization Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Agriculture Food Industry (Safety, Labeling, etc.)
Lobbying Issues
DNA testing in general. H.R. 4614, the Katie Sepich Enhanced DNA Collection Act of 2010.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Changes to tax code affecting international deferral.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Corporate governance provisions in S. 3217, Restoring American Financial Stability Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Financial Institutions/Investments/Securities
4th Quarter, 2009
In Q4, Peck, Madigan, Jones & Stewart, Inc. lobbied for LIFE TECHNOLOGIES CORPORATION , earning $15,000. The report was filed on Jan. 20, 2010.
Original Filing: 300248093.xml
Lobbying Issues
H.R.1260/S.515, Patent Reform Act of 2009; and Research Use Exemption.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R.1260/S.515, Patent Reform Act of 2009; and Research Use Exemption.
DNA testing in general.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R.2749, Food Safety Enhancement Act of 2009; and S.510, FDA Food Safety Modernization Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Agriculture Food Industry (Safety, Labeling, etc.)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
3rd Quarter, 2009
In Q3, Peck, Madigan, Jones & Stewart, Inc. lobbied for LIFE TECHNOLOGIES CORPORATION , earning $30,000. The report was filed on Oct. 20, 2009.
Original Filing: 300220266.xml
Lobbying Issues
H.R.1260/S.515, Patent Reform Act of 2009; and Research Use Exemption.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark Science/Technology
Lobbying Issues
H.R.2749, Food Safety Enhancement Act of 2009; and S.510, FDA Food Safety Modernization Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Agriculture Food Industry (Safety, Labeling, etc.)
Lobbying Issues
P.L.111-32, Supplemental Appropriations Act 2009, specifically funding for pandemic flu; and NIH funding in general.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2009
In Q2, Peck, Madigan, Jones & Stewart, Inc. lobbied for LIFE TECHNOLOGIES CORPORATION , earning $30,000. The report was filed on July 20, 2009.
Original Filing: 300188859.xml
Lobbying Issues
S. 515/H.R. 1260, Patent Reform Act of 2009; and Research Use Exemption.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
S. 515/H.R. 1260, Patent Reform Act of 2007; and Research Use Exemption.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 2749, Food Safety Enhancement Act of 2009; and S.510, FDA Food Safety Modernization Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Agriculture Food Industry (Safety, Labeling, etc.)
Lobbying Issues
H.R. 2346/S.1054.
FY2009 Supplemental Appropriations Bill, funding for pandemic flu
NIH funding in general.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2009
In Q1, Peck, Madigan, Jones & Stewart, Inc. (formerly Johnson, Madigan, Peck, Boland & Stewart, Inc.) lobbied for LIFE TECHNOLOGIES CORPORATION (FORMERLY INVITROGEN CORPORATION) , earning $30,000. The report was filed on April 20, 2009.
Original Filing: 300163137.xml
Lobbying Issues
S. 515/ H.R. 1260, The Patent Reform Act of 2009; and Research Use Exemption.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
S. 515/ H.R. 1260: Patent Reform Act of 2007; and Research Use Exemption.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Food safety legislation, including HR.875, Food Safety Modernization Act; HR.1332, Safe FEAST Act; HR.759, FDA Globalization Act; and S.510, FDA Food Safety Modernization Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Agriculture Food Industry (Safety, Labeling, etc.)
4th Quarter, 2008
In Q4, JOHNSON, MADIGAN, PECK, BOLAND & STEWART, INC. lobbied for INVITROGEN CORPORATION , earning $30,000. The report was filed on Jan. 21, 2009.
Original Filing: 300133823.xml
Lobbying Issues
HR.1908/S.1145, Patent Reform Act of 2007; and Research Use Exemption.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark Science/Technology
3rd Quarter, 2008
In Q3, JOHNSON, MADIGAN, PECK, BOLAND & STEWART, INC. lobbied for INVITROGEN CORPORATION , earning $30,000. The report was filed on Oct. 20, 2008.
Original Filing: 300107646.xml
Lobbying Issues
HR.1908/S.1145, Patent Reform Act of 2007; and Research Use Exemption.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark Science/Technology
2nd Quarter, 2008
In Q2, JOHNSON, MADIGAN, PECK, BOLAND & STEWART, INC. lobbied for INVITROGEN CORPORATION , earning $30,000. The report was filed on July 21, 2008.
Original Filing: 300076863.xml
Lobbying Issues
HR.1908/S.1145, Patent Reform Act of 2007; and Research Use Exemption.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark Science/Technology
1st Quarter, 2008
In Q1, JOHNSON, MADIGAN, PECK, BOLAND & STEWART, INC. lobbied for INVITROGEN CORPORATION , earning $20,000. The report was filed on April 18, 2008.
Original Filing: 300044981.xml
Lobbying Issues
HR.1908/S.1145, Patent Reform Act of 2007; and Research Use Exemption.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark Science/Technology
0th Quarter, 2007
In MM, JOHNSON, MADIGAN, PECK, BOLAND & STEWART, INC. lobbied for INVITROGEN CORPORATION , earning $40,000. The report was filed on July 26, 2007.
Original Filing: 200041686.xml
Lobbying Issues
HR.1908/S.1145, Patent Reform Act of 2007; and Research Use Exemption.
Type of Issue
Copyright/Patent/Trademark Science/Technology
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate